ActX Joins Greenway Online Marketplace for Comprehensive Health IT Solutions, Offering Integrated Genomic Decision Support

SEATTLE--ActX today announced it has joined the Greenway Health online Marketplace of value-added partners for users of Greenway’s integrated electronic health record (EHR) and practice management solutions.

Being named a Marketplace-approved partner signifies cooperative efforts between ActX and Greenway to provide comprehensive, mission-critical health IT solutions that support the delivery of high-quality, cost-effective care.

ActX’s innovative solution makes genomics practical for Greenway clients, ushering in a new era of precision medicine. Based on affordable patient DNA testing, ActX checks each prescription for possible adverse reactions as well as efficacy issues using the patient’s own genetic code. In addition, the ActX application alerts the physician about any serious, actionable medical risks. The ActX – Greenway integrated solution is available today, and delivers the actionable, evidence-based information physicians need, in a way they can trust.

“We’re extremely excited to be making the vision of precision medicine a reality for Greenway users,” says Dr. Andrew Ury, ActX CEO. “Greenway is a market leader in EHR software and services, and we’re proud to be offering genomic decision support to their physicians within Greenway’s standard workflow.”

“Rapid innovation is essential to the development of a sustainable healthcare system, and the Greenway Marketplace gives customers the means to evaluate and select innovative solutions relative to Greenway,” said Greg Shilling, Greenway Vice President of Corporate Development. “We’re pleased to partner with ActX for mutual promotion of its genomic decision support solution to customers seeking to improve their ability to deliver care.”

About ActX:

Founded in 2012, ActX helps physicians make better decisions about medical treatment, using a patient’s genetic information to guide therapy. Integrated into a physician’s normal software tools (the electronic medical record) and workflow, ActX analyzes the patient’s genetic information in real time and, for example, alerts the physician if a medication is unlikely to be effective or will cause side effects. ActX can also warn the physician about serious, actionable medical risks. For more information about ActX and taking the next step towards precision medicine, visit us at www.actx.com, contact us at info@actx.com or call 888-998-2289.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.